Table 4.
Goserelin, buserelin, and triptorelin quantitation in patients’ blood plasma samples.
| Patient No. | Received Drug, Active Substance, Dose | Duration of the Received Therapy |
Day of the Sample Collection |
Measured Concentration/ng/mL |
|---|---|---|---|---|
| 1 | Zoladex®, goserelin acetate, 10.8 mg |
6 months | 29th/84 | 13.57 |
| 2 | Zoladex®, goserelin acetate, 3.6 mg |
9 days | 8th/28 | 0.95 |
| 3 | Zoladex®, goserelin acetate, 10.8 mg |
2 months | 59th/84 | 0.55 |
| 4 | Zoladex®, goserelin acetate, 10.8 mg |
3 days | 3rd/84 | - |
| 5 | Triptorelin-long®, triptorelin acetate, 11.25 mg | 3 months | 83rd/84 | - |
| 6 | Zoladex®, goserelin acetate, 10.8 mg |
3 months | 74th/84 | - |
| 7 | Zoladex®, goserelin acetate, 10.8 mg |
8 months | 10th/84 | 7.81 |
| 8 | Zoladex®, goserelin acetate, 3.6 mg |
2 years | 16th/28 | 16.23 |
| 9 | Buserelin-depo®, buserelin acetate, 3.75 mg | 2 years | 27th/28 | - |